title: Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?
abstract: Pleiotropic effects are now described for the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (or statins) that might have utility in the context of chronic inflammatory autoimmune disease. Here we discuss the pharmacology and established uses of statins and in this context describe potential anti-inflammatory and immune-modulatory effects. An extensive in vitro data set defines roles for statins in modifying endothelial function, particularly with respect to adhesion molecule expression and apoptosis. Broader effects on leukocyte function have now emerged including altered adhesion molecule expression, cytokine and chemokine release and modulation of development of adaptive immune responses via altered MHC class II upregulation. In vivo data in several inflammatory models, including collagen-induced inflammatory arthritis and experimental autoimmune encephalomyelitis, suggest that such effects might have immune-modulatory potential. Finally, a recent clinical trial has demonstrated immunomodulatory effects for statins in patients with rheumatoid arthritis. Together with their known vasculoprotective effects, this growing body of evidence provides compelling support for longer-term trials of statin therapy in human disease such as rheumatoid arthritis.
authors.affiliation: Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, UK.
authors.forename: David W
authors.initials: DW
authors.lastname: McCarey
authors.forename: Naveed
authors.initials: N
authors.lastname: Sattar
authors.forename: Iain B
authors.initials: IB
authors.lastname: McInnes
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001169:Arthritis, Experimental / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001327:Autoimmune Diseases / Q000188:drug therapy*; D015815:Cell Adhesion Molecules / Q000378:metabolism; D018925:Chemokines / Q000378:metabolism; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000378:metabolism; D004311:Double-Blind Method; D004353:Drug Evaluation, Preclinical; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D007155:Immunologic Factors / Q000494:pharmacology* / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy*; D016030:Kidney Transplantation; D051379:Mice; D015394:Molecular Structure; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D051381:Rats
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000924:Anticholesteremic Agents; D015815:Cell Adhesion Molecules; D018925:Chemokines; D016207:Cytokines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007155:Immunologic Factors
references.citation: N Engl J Med. 1995 Nov 16;333(20):1301-7
references.pmid: 7566020
references.citation: J Immunol. 2003 Feb 1;170(3):1524-30
references.pmid: 12538717
references.citation: Transplantation. 1996 May 27;61(10):1469-74
references.pmid: 8633373
references.citation: J Immunol. 2004 Mar 1;172(5):2903-8
references.pmid: 14978092
references.citation: J Atheroscler Thromb. 2002;9(4):178-83
references.pmid: 12226549
references.citation: Atherosclerosis. 2002 May;162(1):179-85
references.pmid: 11947912
references.citation: Nature. 2002 Nov 7;420(6911):78-84
references.pmid: 12422218
references.citation: JAMA. 1996 Jan 10;275(2):128-33
references.pmid: 8531308
references.citation: Biochem Pharmacol. 2004 Jan 15;67(2):303-13
references.pmid: 14698043
references.citation: Clin Chim Acta. 2003 Dec;338(1-2):17-24
references.pmid: 14637261
references.citation: Biochemistry (Mosc). 2002 Jan;67(1):85-91
references.pmid: 11841343
references.citation: JAMA. 2001 Jul 4;286(1):64-70
references.pmid: 11434828
references.citation: Lancet. 2004 Jun 19;363(9426):2015-21
references.pmid: 15207950
references.citation: Kidney Int. 2003 Jan;63(1):96-106
references.pmid: 12472772
references.citation: Atherosclerosis. 2004 Jan;172(1):85-93
references.pmid: 14709361
references.citation: J Am Coll Cardiol. 2001 Mar 1;37(3):800-7
references.pmid: 11693755
references.citation: N Engl J Med. 2004 Apr 1;350(14):1387-97
references.pmid: 15070788
references.citation: Thromb Res. 2002 Feb 15;105(4):285-90
references.pmid: 12031821
references.citation: Trends Pharmacol Sci. 1998 Jan;19(1):26-37
references.pmid: 9509899
references.citation: Nat Immunol. 2002 Apr;3(4):360-5
references.pmid: 11896391
references.citation: Curr Control Trials Cardiovasc Med. 2001;2(5):205-207
references.pmid: 11806796
references.citation: Int J Clin Pharmacol Ther. 2003 Sep;41(9):397-401
references.pmid: 14518599
references.citation: J Pharmacol Exp Ther. 2002 Aug;302(2):601-5
references.pmid: 12130721
references.citation: Nat Med. 2001 Jun;7(6):687-92
references.pmid: 11385505
references.citation: Arterioscler Thromb Vasc Biol. 2001 Jan;21(1):115-21
references.pmid: 11145942
references.citation: Am J Nephrol. 2003 Jan-Feb;23(1):13-7
references.pmid: 12373076
references.citation: Inflamm Res. 2002 Feb;51(2):58-62
references.pmid: 11926313
references.citation: Circulation. 2002 Mar 5;105(9):1135-43
references.pmid: 11877368
references.citation: Cardiovasc Res. 2004 Apr 1;62(1):105-11
references.pmid: 15023557
references.citation: Lancet. 2002 Jul 6;360(9326):7-22
references.pmid: 12114036
references.citation: Nat Med. 2000 Dec;6(12):1399-402
references.pmid: 11100127
references.citation: Arthritis Rheum. 2001 Jun;44(6):1234-6
references.pmid: 11407680
references.citation: Br J Pharmacol. 2002 Jan;135(1):284-92
references.pmid: 11786505
references.citation: Arthritis Res. 2000;2(5):374-8
references.pmid: 11094451
references.citation: Circ Res. 2002 Oct 18;91(8):696-703
references.pmid: 12386146
references.citation: J Clin Endocrinol Metab. 2002 Feb;87(2):563-8
references.pmid: 11836286
references.citation: Am J Cardiol. 1994 May 26;73(14):3D-11D
references.pmid: 8198021
references.citation: Circ Res. 2003 Nov 14;93(10):948-56
references.pmid: 14563711
references.citation: J Clin Invest. 1997 Dec 1;100(11):2671-9
references.pmid: 9389730
references.citation: Atherosclerosis. 2000 Oct;152(2):359-66
references.pmid: 10998463
references.citation: Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1784-9
references.pmid: 12426205
references.citation: Arterioscler Thromb Vasc Biol. 2000 Feb;20(2):556-62
references.pmid: 10669656
references.citation: Kidney Int. 2001 Nov;60(5):1990-7
references.pmid: 11703619
references.citation: Circulation. 1999 Nov 23;100(21):2124-6
references.pmid: 10571968
references.citation: Drug Metab Dispos. 2001 Mar;29(3):282-8
references.pmid: 11181496
references.citation: Lancet. 1994 Nov 19;344(8934):1383-9
references.pmid: 7968073
references.citation: N Engl J Med. 1995 Sep 7;333(10):621-7
references.pmid: 7637722
references.citation: Atherosclerosis. 2002 Jan;160(1):49-58
references.pmid: 11755922
references.citation: Am J Cardiol. 1998 Aug 27;82(4B):3J-10J
references.pmid: 9737640
references.citation: Am J Cardiol. 2001 Sep 1;88(5):504-8
references.pmid: 11524058
references.citation: Circulation. 1997 Sep 2;96(5):1398-402
references.pmid: 9315523
references.citation: Int J Cardiol. 2001 Feb;77(2-3):247-53
references.pmid: 11182189
references.citation: JAMA. 2001 Apr 4;285(13):1711-8
references.pmid: 11277825